$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

$clov Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000180117022000015 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$432.0M	$1.472B	$0.00
YoY Change		118.76%
Cost Of Revenue		$1.551B
YoY Change		162.87%
Gross Profit		-$79.18M
YoY Change		-195.62%
Gross Profit Margin		-5.38%
Selling, General & Admin	$114.2M	$445.7M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$848.0K	$300.0K
YoY Change		-40.0%
% of Gross Profit
Operating Expenses	$618.8M	$2.109B	$4.400M
YoY Change	13964.2%	175.47%
Operating Profit		-$637.0M
YoY Change		587.1%
Interest Expense	-$412.0K	$3.229M	$0.00
YoY Change		-91.03%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$13.68M
YoY Change
Pretax Income	-$187.2M	-$587.8M	-$4.400M
YoY Change	4154.57%	8620.42%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$187.2M	-$587.8M	-$4.400M
YoY Change	4154.57%	330.93%	24856.04%
Net Earnings / Revenue	-43.33%	-39.93%
Basic Earnings Per Share		-$1.42
Diluted Earnings Per Share	-$445.3K	-$1.42	-$42.51K
COMMON SHARES
Basic Shares Outstanding		412.9M shares
Diluted Shares Outstanding		412.9M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$321.1M	$627.9M	$92.35M
YoY Change	247.71%	2142.39%
Cash & Equivalents	$300.0M	$300.0M	$92.35M
Short-Term Investments	$21.13M	$327.9M	$0.00
Other Short-Term Assets	$18.02M	$62.35M	$299.0K
YoY Change	5927.42%	20684.67%
Inventory
Prepaid Expenses	$9.409M		$7.830M
Receivables
Other Receivables
Total Short-Term Assets	$752.5M	$752.5M	$189.8M
YoY Change	296.53%	2559.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.287M	$7.654M	$2.078M
YoY Change	10.06%
Goodwill	$1.200M		$1.200M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$175.9M	$828.1M
YoY Change	-100.0%	-78.75%
Other Assets	$10.43M	$10.43M	$8.885M
YoY Change	17.41%
Total Long-Term Assets	$198.3M	$198.3M	$77.47M
YoY Change	155.92%	-76.06%	77102.88%
TOTAL ASSETS
Total Short-Term Assets	$752.5M	$752.5M	$189.8M
Total Long-Term Assets	$198.3M	$198.3M	$77.47M
Total Assets	$950.8M	$950.8M	$267.3M
YoY Change	255.77%	11.02%	266230.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$28.13M	$28.13M
YoY Change
Accrued Expenses	$18.21M	$18.21M	$4.935M
YoY Change	268.94%	256.98%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$800.0K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$0.00		$20.80M
YoY Change	-100.0%
Total Short-Term Liabilities	$372.6M	$372.6M	$164.2M
YoY Change	126.89%	999.19%	139103.4%
LONG-TERM LIABILITIES
Long-Term Debt	$19.94M	$19.94M	$106.4M
YoY Change	-81.26%
Other Long-Term Liabilities	$14.10M	$18.93M	$13.12M
YoY Change	7.46%	-34.74%
Total Long-Term Liabilities	$34.03M	$38.86M	$119.5M
YoY Change	-71.53%	34.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$372.6M	$372.6M	$164.2M
Total Long-Term Liabilities	$34.03M	$38.86M	$119.5M
Total Liabilities	$411.5M	$415.4M	$432.7M
YoY Change	-4.9%	560.4%	366664.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.617B		-$1.029B
YoY Change	57.12%		5836108.95%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$147.0K		$0.00
YoY Change
Treasury Stock Shares	14.73K shares		0.000 shares
Shareholders Equity	$535.4M	$535.4M	-$617.1M
YoY Change
Total Liabilities & Shareholders Equity	$950.8M	$950.8M	$267.3M
YoY Change	255.77%	11.02%	266230.5%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$187.2M	-$587.8M	-$4.400M
YoY Change	4154.57%	330.93%	24856.04%
Depreciation, Depletion And Amortization	$848.0K	$300.0K
YoY Change		-40.0%
Cash From Operating Activities	-$80.18M	-$282.3M	-$1.130M
YoY Change	6995.22%	138.25%	6309.17%
INVESTING ACTIVITIES
Capital Expenditures	-$238.0K	$723.0K
YoY Change		4.33%
Acquisitions		$0.00
YoY Change
Other Investing Activities	-$106.3M	-$434.7M	$0.00
YoY Change		-47.5%
Cash From Investing Activities	-$106.5M	-$435.4M	$0.00
YoY Change		-416.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$283.6M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	284.4M	$925.4M	29.00M
YoY Change	880.59%	15734.92%	164383.01%
NET CHANGE
Cash From Operating Activities	-80.18M	-$282.3M	-1.130M
Cash From Investing Activities	-106.5M	-$435.4M	0.000
Cash From Financing Activities	284.4M	$925.4M	29.00M
Net Change In Cash	97.70M	$207.6M	27.87M
YoY Change	250.57%	738.87%
FREE CASH FLOW
Cash From Operating Activities	-$80.18M	-$282.3M	-$1.130M
Capital Expenditures	-$238.0K	$723.0K
Free Cash Flow	-$79.94M	-$283.0M
YoY Change		137.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001801170
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Registrant Name EntityRegistrantName	CLOVER HEALTH INVESTMENTS, CORP. /DE
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39252
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1515192
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	3401 Mallory Lane
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Franklin
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37067
CY2021	dei	City Area Code CityAreaCode	201
CY2021	dei	Local Phone Number LocalPhoneNumber	432-2133
CY2021	dei	Security12g Title Security12gTitle	Class A Common Stock, par value $0.0001 per share
CY2021	dei	Trading Symbol TradingSymbol	CLOV
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	5469360178	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	299968000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92348000	USD
CY2021Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	293851000	USD
CY2020Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	4098000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	21142000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	21131000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2021Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	307000	USD
CY2020Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	266000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	305000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	265000	USD
CY2021Q4	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	34923000	USD
CY2020Q4	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	34829000	USD
CY2021Q4	us-gaap	Other Receivables OtherReceivables	14282000	USD
CY2020Q4	us-gaap	Other Receivables OtherReceivables	11368000	USD
CY2021Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	48042000	USD
CY2020Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	38745000	USD
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12613000	USD
CY2020Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9409000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7830000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18022000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	299000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	752546000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	189782000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	177527000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	53953000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	175604000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	53963000	USD
CY2021Q4	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	364000	USD
CY2020Q4	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	471000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	335000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	429000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2287000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2078000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5367000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7882000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	4233000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	4233000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10432000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8885000	USD
CY2021Q4	us-gaap	Assets Assets	950804000	USD
CY2020Q4	us-gaap	Assets Assets	267252000	USD
CY2021Q4	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	138604000	USD
CY2020Q4	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	102429000	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2320000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1547000	USD
CY2021Q4	clov	Direct Contracting Performance Year Obligation Current DirectContractingPerformanceYearObligationCurrent	36891000	USD
CY2020Q4	clov	Direct Contracting Performance Year Obligation Current DirectContractingPerformanceYearObligationCurrent	0	USD
CY2021Q4	clov	Direct Contracting Payable Current DirectContractingPayableCurrent	37773000	USD
CY2020Q4	clov	Direct Contracting Payable Current DirectContractingPayableCurrent	0	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28129000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30671000	USD
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	15147000	USD
CY2020Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	3978000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3059000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4795000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	20803000	USD
CY2021Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	110628000	USD
CY2020Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	0	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	73000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	372624000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	164228000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19938000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	106413000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	44810000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	97782000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4830000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6349000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14095000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13116000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	411487000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	432698000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	155387025	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	139444346	shares
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	470256000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2154187000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	411867000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1934000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1616738000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1028982000	USD
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	14730	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	147000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	535414000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-617096000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	3903000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	3903000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	539317000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-613193000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	950804000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	267252000	USD
CY2021Q1	clov	Common Stock Exchange Ratio CommonStockExchangeRatio	2.0681
CY2021	us-gaap	Ceded Premiums Earned CededPremiumsEarned	489000	USD
CY2020	us-gaap	Ceded Premiums Earned CededPremiumsEarned	599000	USD
CY2019	us-gaap	Ceded Premiums Earned CededPremiumsEarned	832000	USD
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	799414000	USD
CY2020	us-gaap	Premiums Earned Net PremiumsEarnedNet	665698000	USD
CY2019	us-gaap	Premiums Earned Net PremiumsEarnedNet	456926000	USD
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	667639000	USD
CY2020	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	USD
CY2019	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	USD
CY2021	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	4943000	USD
CY2020	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	7190000	USD
CY2019	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	5340000	USD
CY2021	us-gaap	Revenues Revenues	1471996000	USD
CY2020	us-gaap	Revenues Revenues	672888000	USD
CY2019	us-gaap	Revenues Revenues	462266000	USD
CY2021	clov	Other Medical Costs OtherMedicalCosts	7637000	USD
CY2020	clov	Other Medical Costs OtherMedicalCosts	4650000	USD
CY2019	clov	Other Medical Costs OtherMedicalCosts	3009000	USD
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	260458000	USD
CY2020	us-gaap	Labor And Related Expense LaborAndRelatedExpense	71256000	USD
CY2019	us-gaap	Labor And Related Expense LaborAndRelatedExpense	91626000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	185287000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	120830000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	95701000	USD
CY2021	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	110628000	USD
CY2020	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	-17128000	USD
CY2019	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	7523000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1246000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	555000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	551000	USD
CY2021	us-gaap	Other General Expense OtherGeneralExpense	191000	USD
CY2020	us-gaap	Other General Expense OtherGeneralExpense	0	USD
CY2019	us-gaap	Other General Expense OtherGeneralExpense	363000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	2108988000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	765595000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	645465000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-636992000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-92707000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-183199000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-66146000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	80328000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2909000	USD
CY2021	us-gaap	Interest Expense InterestExpense	3229000	USD
CY2020	us-gaap	Interest Expense InterestExpense	35990000	USD
CY2019	us-gaap	Interest Expense InterestExpense	23155000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13681000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21118000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15913000	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	93751000	USD
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-138561000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-587756000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-136392000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-363737000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.42
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.42
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.14
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.14
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	412922424	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	412922424	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88691582	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88691582	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87829419	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87829419	shares
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-1944000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-36000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	46000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-488537000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-589700000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-136428000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-363691000	USD
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-502574000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	601000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3301000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	46000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	373826000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-363737000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-488537000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1748000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7078000	USD
CY2020	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	957000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-36000	USD
CY2020	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	-3903000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-136392000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-613193000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-613193000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6144000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	163723000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1944000	USD
CY2021	clov	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	139444346	shares
CY2021	clov	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	447747000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	447747000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	16059000	USD
CY2021	clov	Stock Issued During Period Value Business Combination And Offering StockIssuedDuringPeriodValueBusinessCombinationAndOffering	666241000	USD
CY2021	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	USD
CY2021	clov	Conversion From Class A To Class B Common Stock ConversionFromClassAToClassBCommonStock	0	USD
CY2021	clov	Capital Contribution For Extinguishment Of Debt CapitalContributionForExtinguishmentOfDebt	126795000	USD
CY2021	clov	Acquisition Of Public And Private Placement Warrants AcquisitionOfPublicAndPrivatePlacementWarrants	147582000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	283775000	USD
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	147000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-587756000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	539317000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-587756000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-136392000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-363737000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-23000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	163723000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1246000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	555000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	551000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13681000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21118000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15913000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	7078000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	3301000	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	28334000	USD
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	11633000	USD
CY2021	clov	Increase Decrease In Fair Value Adjustment Of Warrants IncreaseDecreaseInFairValueAdjustmentOfWarrants	-66146000	USD
CY2019	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	7546000	USD
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2914000	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	111000	USD
CY2020	clov	Increase Decrease In Fair Value Adjustment Of Warrants IncreaseDecreaseInFairValueAdjustmentOfWarrants	80328000	USD
CY2019	clov	Increase Decrease In Fair Value Adjustment Of Warrants IncreaseDecreaseInFairValueAdjustmentOfWarrants	2909000	USD
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-93751000	USD
CY2019	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	138561000	USD
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	200000	USD
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-195000	USD
CY2019	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-2857000	USD
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-53000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	1114000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1632000	USD
CY2021	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-94000	USD
CY2020	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-21604000	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5865000	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-4115000	USD
CY2021	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	96000	USD
CY2020	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	-481000	USD
CY2019	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	-63610000	USD
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	12613000	USD
CY2020	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2019	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1579000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	6473000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-600000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	19757000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1003000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	470000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9297000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12926000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14511000	USD
CY2021	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	3591000	USD
CY2021	clov	Increase Decrease In Premium Deficiency Reserve IncreaseDecreaseInPremiumDeficiencyReserve	-110628000	USD
CY2020	clov	Increase Decrease In Premium Deficiency Reserve IncreaseDecreaseInPremiumDeficiencyReserve	17128000	USD
CY2020	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	3257000	USD
CY2019	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-11933000	USD
CY2021	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	36948000	USD
CY2020	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	26090000	USD
CY2019	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	23882000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5307000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10845000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6298000	USD
CY2021	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	11169000	USD
CY2020	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	186000	USD
CY2019	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-2235000	USD
CY2019	clov	Increase Decrease In Premium Deficiency Reserve IncreaseDecreaseInPremiumDeficiencyReserve	-7523000	USD
CY2021	us-gaap	Increase Decrease In Reinsurance Payables IncreaseDecreaseInReinsurancePayables	0	USD
CY2020	us-gaap	Increase Decrease In Reinsurance Payables IncreaseDecreaseInReinsurancePayables	0	USD
CY2019	us-gaap	Increase Decrease In Reinsurance Payables IncreaseDecreaseInReinsurancePayables	-64414000	USD
CY2021	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-68000	USD
CY2020	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	2677000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	979000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1378000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	168000	USD
CY2021	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	36891000	USD
CY2020	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	0	USD
CY2019	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	0	USD
CY2021	clov	Increase Decrease In Direct Contracting Payable IncreaseDecreaseInDirectContractingPayable	37773000	USD
CY2020	clov	Increase Decrease In Direct Contracting Payable IncreaseDecreaseInDirectContractingPayable	0	USD
CY2019	clov	Increase Decrease In Direct Contracting Payable IncreaseDecreaseInDirectContractingPayable	0	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4331000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3703000	USD
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	14805000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1180000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-282326000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-118498000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159875000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	876252000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	174318000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	505545000	USD
CY2021	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	126862000	USD
CY2020	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	248664000	USD
CY2019	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	269205000	USD
CY2021	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSale	314666000	USD
CY2020	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSale	63751000	USD
CY2019	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSale	46415000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	9220000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	363000	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	30925000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	723000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	693000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-435447000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	137404000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181908000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	20000000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	343410000	USD
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	98000	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	18752000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	9670000	USD
CY2021	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	6144000	USD
CY2021	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	85000	USD
CY2020	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	1748000	USD
CY2019	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	601000	USD
CY2021	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	666241000	USD
CY2020	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	0	USD
CY2019	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	0	USD
CY2021	clov	Payments For Repurchase And Cancellation Of Common Stock PaymentsForRepurchaseAndCancellationOfCommonStock	0	USD
CY2020	clov	Payments For Repurchase And Cancellation Of Common Stock PaymentsForRepurchaseAndCancellationOfCommonStock	957000	USD
CY2019	clov	Payments For Repurchase And Cancellation Of Common Stock PaymentsForRepurchaseAndCancellationOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	390000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	283775000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2019	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	147000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	0	USD
CY2020	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	3903000	USD
CY2019	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	925393000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5844000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	333978000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	207620000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	24750000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7805000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92348000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67598000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75403000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299968000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92348000	USD
CY2020	us-gaap	Loans Assumed1 LoansAssumed1	0	USD
CY2020	clov	Warrants Issued In Connection With Notes Payable Fair Value WarrantsIssuedInConnectionWithNotesPayableFairValue	0	USD
CY2019	clov	Warrants Issued In Connection With Notes Payable Fair Value WarrantsIssuedInConnectionWithNotesPayableFairValue	17672000	USD
CY2021	us-gaap	Loans Assumed1 LoansAssumed1	0	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67598000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1677000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4578000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	6257000	USD
CY2021	clov	Health Insurance Industry Fee Expense HealthInsuranceIndustryFeeExpense	0	USD
CY2020	clov	Health Insurance Industry Fee Expense HealthInsuranceIndustryFeeExpense	8022000	USD
CY2019	clov	Health Insurance Industry Fee Expense HealthInsuranceIndustryFeeExpense	0	USD
CY2021	clov	Warrants Issued In Connection With Notes Payable Fair Value WarrantsIssuedInConnectionWithNotesPayableFairValue	0	USD
CY2019	us-gaap	Loans Assumed1 LoansAssumed1	30416000	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	447747000	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	Reportable_segment
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	16059000	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2021	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	126795000	USD
CY2020	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	USD
CY2019	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	USD
CY2021	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	97782000	USD
CY2020	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	0	USD
CY2019	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	0	USD
CY2021	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	147582000	USD
CY2020	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	0	USD
CY2019	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	0	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	81283000	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2021	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1076000	USD
CY2020	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	42000	USD
CY2019	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	459000	USD
CY2021Q4	clov	Direct Contracting Shared Savings And Losses Percent DirectContractingSharedSavingsAndLossesPercent	1.000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and the accompanying notes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The areas involving the most significant use of estimates are the amounts of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Corporation cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Corporation assumes prior to payment of claims. If the Corporation's actual experience is different from its assumptions or estimates, the Corporation's reserves may prove inadequate. As a result, the Corporation would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Corporation's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Corporation's investment securities, goodwill and other intangible assets, reinsurance, premium deficiency reserve, warrants, embedded derivative related to the convertible securities, stock-based compensation, recoveries from third parties for coordination of benefits, Direct Contracting benchmark specifically cost trend and risk score estimates that can develop over time, and final determination of medical cost adjustment pools.</span></div>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To conform to the current period presentation, prepaid expenses, which were previously included in other assets, current, are presented as a separate line item in the prior year’s Consolidated Balance Sheet. Certain amounts in the prior years’ Consolidated Statements of Cash Flows have been reclassified to conform to the current year’s presentation, primarily related to the amortization of notes and securities discounts and debt issuance costs, change in fair value of warrants payable and amortization of warrants, prepaid expenses, and other assets. Additionally, certain amounts in the prior years’ Consolidated Statement of Operations and Comprehensive Loss have been reclassified to conform to the current year’s presentation, primarily related to MA net medical claims incurred and other medical costs. These reclassifications had no effect on the previously reported Consolidated Financial Statements.</span></div>
CY2019	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2020	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2021	us-gaap	Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for expected credit losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation assesses outstanding receivables at each period for credit risk. The majority of receivables are from CMS, a United States government entity that presents very limited credit risk.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Corporation to concentrations of credit risk consist principally of cash and cash equivalents. Cash and cash equivalents are held with financial institutions of high quality. Balances may exceed the amount of insurance provided on such balances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ceding of insurance does not legally discharge the Corporation from its primary liability for the full amount of the policy coverage, and therefore the Corporation will be required to pay the loss and bear collection risk if the reinsurer fails to meet its obligations under the reinsurance agreement. To minimize exposure to significant losses from reinsurance insolvencies, the Corporation evaluates the financial condition of its reinsurers and monitors concentrations of credit risk with its reinsurers.</span></div>
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	0	USD
CY2021Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	0	USD
CY2020	clov	Health Insurance Industry Fee Expense HealthInsuranceIndustryFeeExpense	8000000	USD
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2019	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	822300000	USD
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	38533271	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	38533271	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	640000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	40000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Accumulated Loss HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	9000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	671000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	198669000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1944000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196735000	USD
CY2021Q4	us-gaap	Investments Investments	199309000	USD
CY2021Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	50000	USD
CY2020Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	94000	USD
CY2021Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1953000	USD
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	197406000	USD
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	694000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	43000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Continuous Unrealized Loss Position Accumulated Loss HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	0	USD
CY2020Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	737000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53953000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	51000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	41000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	53963000	USD
CY2020Q4	us-gaap	Investments Investments	54647000	USD
CY2020Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	41000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	54700000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsFairValue	147000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	0	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	307000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	21142000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	305000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	21131000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	15000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	16000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	172564000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	170820000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	210000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	201000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	4963000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4784000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsNetCarryingAmount	110000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	USD
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	640000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	671000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	198669000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	196735000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositionsYearOne	18	position
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	544000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	2976000	USD
CY2019	us-gaap	Net Investment Income NetInvestmentIncome	4539000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOne	187251000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneAccumulatedLoss	1555000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLonger	7902000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	398000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPosition	195153000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionAccumulatedLoss	1953000	USD
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions12MonthsOrLonger	4	position
CY2021Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	22	position
CY2021Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	126862000	USD
CY2020	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	248664000	USD
CY2019	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	269205000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1836000	USD
CY2021	us-gaap	Depreciation Depreciation	300000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1.000
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.040
CY2021	clov	Proceeds From Maturity Of Investment Secutities ProceedsFromMaturityOfInvestmentSecutities	314666000	USD
CY2020	clov	Proceeds From Maturity Of Investment Secutities ProceedsFromMaturityOfInvestmentSecutities	63751000	USD
CY2019	clov	Proceeds From Maturity Of Investment Secutities ProceedsFromMaturityOfInvestmentSecutities	55635000	USD
CY2021	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	24000	USD
CY2020	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	1117000	USD
CY2019	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	114000	USD
CY2021	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	77000	USD
CY2020	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	3000	USD
CY2019	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	3000	USD
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-53000	USD
CY2020	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1114000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	111000	USD
CY2021Q4	us-gaap	Deposits Deposits	11100000	USD
CY2020Q4	us-gaap	Deposits Deposits	7500000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196735000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	196735000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	53963000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	53963000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	44810000	USD
CY2020Q4	clov	Warrant Liability Fair Value Disclosure WarrantLiabilityFairValueDisclosure	97782000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	142592000	USD
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.10
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2287000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2078000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4599000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3914000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2312000	USD
CY2020	us-gaap	Depreciation Depreciation	500000	USD
CY2019	us-gaap	Depreciation Depreciation	600000	USD
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	200000	USD
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	100000	USD
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3000000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	1200000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	1200000	USD
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2021	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in the liability for unpaid claims, including claims adjustment expenses, for the years ended December 31, 2021 and 2020, is summarized as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross and net balance, beginning of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,432 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross and net balance, end of period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt double #ffffff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes amounts due to related parties. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Differs from the total unpaid claims amount reported on the Consolidated Balance Sheets due to the fact the figure here excludes unpaid claims for the Corporation’s DCE of $4.6 million as of December 31, 2021.</span></div>
CY2020Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	103976000	USD
CY2019Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	77886000	USD
CY2020	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	599147000	USD
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	15834000	USD
CY2020	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-13715000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	838134000	USD
CY2020	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	585432000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	692116000	USD
CY2020	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	496303000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	113677000	USD
CY2020	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	63039000	USD
CY2021	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	805793000	USD
CY2020	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	559342000	USD
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	136317000	USD
CY2020Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	103976000	USD
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	113700000	USD
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	15800000	USD
CY2020	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-13700000	USD
CY2021	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.842
CY2021Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	2249623000	USD
CY2020	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.828
CY2019Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	962373000	USD
CY2020Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	1547806000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	2385940000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet	136317000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Number Of Reported Claims ShortdurationInsuranceContractsNumberOfReportedClaims	6743886000	claim
CY2019Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	894877000	USD
CY2020Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	1443830000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	2385940000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	2249623000	USD
CY2021Q4	us-gaap	Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet	136317000	USD
CY2021Q1	clov	Reinsurance Excess Loss Coverage Threshold Per Covered Person ReinsuranceExcessLossCoverageThresholdPerCoveredPerson	600000	USD
CY2019	clov	Reinsurance Excess Loss Coverage Threshold Per Covered Person ReinsuranceExcessLossCoverageThresholdPerCoveredPerson	500000	USD
CY2020	clov	Reinsurance Excess Loss Coverage Threshold Per Covered Person ReinsuranceExcessLossCoverageThresholdPerCoveredPerson	500000	USD
CY2021Q4	clov	Coinsurance Percentage CoinsurancePercentage	1
CY2021Q4	clov	Life Insurance Reserves Fully Coinsured By Third Party LifeInsuranceReservesFullyCoinsuredByThirdParty	5300000	USD
CY2020Q4	clov	Life Insurance Reserves Fully Coinsured By Third Party LifeInsuranceReservesFullyCoinsuredByThirdParty	5300000	USD
CY2021Q4	clov	Life Insurance Reserves Coinsurance Percentage LifeInsuranceReservesCoinsurancePercentage	1
CY2020Q4	clov	Annuity Reserve Fully Coinsured To Third Party AnnuityReserveFullyCoinsuredToThirdParty	900000	USD
CY2021Q4	clov	Annuity Reserve Fully Coinsured To Third Party AnnuityReserveFullyCoinsuredToThirdParty	900000	USD
CY2021Q4	clov	Annuity Reserves Transfer Of Risk Percentage AnnuityReservesTransferOfRiskPercentage	1
CY2018Q4	clov	Debt Instrument Convertible Amount DebtInstrumentConvertibleAmount	500000000	USD
CY2020Q4	clov	Debt Conversion Percentage Charge For Dilution DebtConversionPercentageChargeForDilution	0.094
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	20000000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	373800000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	44800000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	44800000	USD
CY2020	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	93800000	USD
CY2019	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	138600000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y7D
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4515000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	4533000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	4552000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	515000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	632000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	654000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	45000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	20000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	58000	USD
CY2021	us-gaap	Sublease Income SubleaseIncome	2727000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	3098000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	989000	USD
CY2021	us-gaap	Lease Cost LeaseCost	2348000	USD
CY2020	us-gaap	Lease Cost LeaseCost	2087000	USD
CY2019	us-gaap	Lease Cost LeaseCost	4275000	USD
CY2021	clov	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	5248000	USD
CY2020	clov	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	4979000	USD
CY2019	clov	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	4804000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1036
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1017
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1005
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3164000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1665000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1319000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1170000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1155000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1486000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9959000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2070000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7889000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.040
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1200000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1200000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1300000	USD
CY2021	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	1.000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1937968	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	163700000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	163723000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7078000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3301000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	435600000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	21872378	shares
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14900000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.36
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.04
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.62
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	52500000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	39200000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.32
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	39300000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5800000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1300000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	139629	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.61
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	122052	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.45
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	7000000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	900000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	clov	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	2267000	USD
CY2020Q4	clov	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	1786000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2950000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-123429000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-28642000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-76385000	USD
CY2021	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesAmount	0	USD
CY2020	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesAmount	6537000	USD
CY2019	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesAmount	3505000	USD
CY2021	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Discount Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesDiscountAmount	2867000	USD
CY2020	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Discount Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesDiscountAmount	4423000	USD
CY2019	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Discount Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesDiscountAmount	3257000	USD
CY2021	clov	Effective Income Tax Rate Reconciliation Debt Issuance Cost Amount EffectiveIncomeTaxRateReconciliationDebtIssuanceCostAmount	0	USD
CY2020	clov	Effective Income Tax Rate Reconciliation Debt Issuance Cost Amount EffectiveIncomeTaxRateReconciliationDebtIssuanceCostAmount	0	USD
CY2019	clov	Effective Income Tax Rate Reconciliation Debt Issuance Cost Amount EffectiveIncomeTaxRateReconciliationDebtIssuanceCostAmount	76000	USD
CY2021	clov	Effective Income Tax Rate Reconciliation Derivative Liability Amount EffectiveIncomeTaxRateReconciliationDerivativeLiabilityAmount	0	USD
CY2020	clov	Effective Income Tax Rate Reconciliation Derivative Liability Amount EffectiveIncomeTaxRateReconciliationDerivativeLiabilityAmount	-19688000	USD
CY2019	clov	Effective Income Tax Rate Reconciliation Derivative Liability Amount EffectiveIncomeTaxRateReconciliationDerivativeLiabilityAmount	29098000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	26000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	13000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	210000	USD
CY2021	clov	Effective Income Tax Rate Reconciliation Health Insurance Industry Fee Amount EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryFeeAmount	0	USD
CY2020	clov	Effective Income Tax Rate Reconciliation Health Insurance Industry Fee Amount EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryFeeAmount	2715000	USD
CY2019	clov	Effective Income Tax Rate Reconciliation Health Insurance Industry Fee Amount EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryFeeAmount	0	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5665000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	350000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-365000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1116000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	112661000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18585000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	39643000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	152423000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2020	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	31100000	USD
CY2019	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	16700000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	207713000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	35374000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2568000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve	23232000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve	0	USD
CY2021Q4	clov	Deferred Tax Assets Unpaid Claim Reserve Discounting DeferredTaxAssetsUnpaidClaimReserveDiscounting	404000	USD
CY2020Q4	clov	Deferred Tax Assets Unpaid Claim Reserve Discounting DeferredTaxAssetsUnpaidClaimReserveDiscounting	335000	USD
CY2021Q4	clov	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1657000	USD
CY2020Q4	clov	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2340000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	164908000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	275865000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2984000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3434000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2472000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	277031000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	163204000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1166000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1704000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1127000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1655000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	39000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	49000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1166000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1704000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	989100000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	725800000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	295100000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	275900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	163200000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-587756000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-136392000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-363737000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-587786000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-136392000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-363737000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	412922424	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	412922424	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88691582	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.14
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88691582	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87829419	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87829419	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.42
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.42
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.14
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	81992991	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	183505007	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	171292096	shares
CY2021Q4	clov	Direct Contracting Risk Mitigation Maximum Percentage Of Performance Year Benchmark DirectContractingRiskMitigationMaximumPercentageOfPerformanceYearBenchmark	0.250
CY2021Q4	clov	Direct Contracting Performance Year Receivable Noncurrent DirectContractingPerformanceYearReceivableNoncurrent	0	USD
CY2021Q4	clov	Direct Contracting Performance Year Obligation Current DirectContractingPerformanceYearObligationCurrent	36891000	USD
CY2021	clov	Direct Contracting Performance Year Receivable Amortization DirectContractingPerformanceYearReceivableAmortization	664224000	USD
CY2021	clov	Direct Contracting Performance Year Obligation Amortization DirectContractingPerformanceYearObligationAmortization	664224000	USD
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	667639000	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021	us-gaap	Ceded Premiums Earned CededPremiumsEarned	489000	USD
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	799414000	USD
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	667639000	USD
CY2021	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	4943000	USD
CY2021	clov	Policyholder Benefits And Claims Incurred Net And Other Medical Costs PolicyholderBenefitsAndClaimsIncurredNetAndOtherMedicalCosts	1551178000	USD
CY2021	us-gaap	Gross Profit GrossProfit	-79182000	USD
CY2021Q4	us-gaap	Assets Assets	950804000	USD
CY2021	us-gaap	Gross Profit GrossProfit	-79182000	USD
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	260458000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	185287000	USD
CY2021	clov	Premium Deficiency Testing Expense Benefit Long Duration Contract Amount PremiumDeficiencyTestingExpenseBenefitLongDurationContractAmount	110628000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1246000	USD
CY2021	us-gaap	Other General Expense OtherGeneralExpense	191000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-66146000	USD
CY2021	us-gaap	Interest Expense InterestExpense	3229000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13681000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-587756000	USD
CY2021Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	128900000	USD
CY2020Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	79400000	USD
CY2021Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	99700000	USD
CY2020Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	75800000	USD
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	14730	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2021Q1	clov	Common Stock Exchange Ratio CommonStockExchangeRatio	2.0681
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	New York, New York
CY2021	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001801170-22-000015-index-headers.html	Edgar Link	pending
0001801170-22-000015-index.html	Edgar Link	pending
0001801170-22-000015.txt	Edgar Link	pending
0001801170-22-000015-xbrl.zip	Edgar Link	pending
a12312021-exx311.htm	Edgar Link	pending
a12312021-exx312.htm	Edgar Link	pending
a12312021-exx321.htm	Edgar Link	pending
a12312021-exx322.htm	Edgar Link	pending
clov-20211231.htm	Edgar Link	pending
clov-20211231.xsd	Edgar Link	pending
clov-20211231_cal.xml	Edgar Link	unprocessable
clov-20211231_def.xml	Edgar Link	unprocessable
clov-20211231_g1.jpg	Edgar Link	pending
clov-20211231_htm.xml	Edgar Link	completed
clov-20211231_lab.xml	Edgar Link	unprocessable
clov-20211231_pre.xml	Edgar Link	unprocessable
consentofindependentregist.htm	Edgar Link	pending
descriptionofsecurities.htm	Edgar Link	pending
exhibit1012.htm	Edgar Link	pending
exhibit1013.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_2012.jpg	Edgar Link	pending
image_20a.jpg	Edgar Link	pending
letteragreementdatedjanuar.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2021 Q4 Form 10-K Financial Statement

#000180117022000015 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2021 Q4 Form 10-K Financial Statement

#000180117022000015 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov